Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients

Psychiatry Research

Volumn 110, Issue 3, 2002, Pages 249-257

  Toyooka, Kazuhiko ^a,b   Asama, Koue ^c   Watanabe, Yuichiro ^a,b   Muratake, Tatsuyuki ^b   Takahashi, Makoto ^b   Someya, Toshiyuki ^b   Nawa, Hiroyuki ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c Ohjima Hospital   (Japan)

Author keywords

BDNF; Haloperidol; Neurotrophin; Platelet; Schizophrenia; Vesicle

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; HALOPERIDOL; NEUROLEPTIC AGENT;

ADULT; ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; THROMBOCYTE COUNT; VOLUNTEER;

ADULT; ANIMALS; ANTIPSYCHOTIC AGENTS; BLOOD PLATELETS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHRONIC DISEASE; FEMALE; HALOPERIDOL; HUMANS; MALE; RATS; SCHIZOPHRENIA;

EID: 0037205782     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(02)00127-0     Document Type: Article

References (41)

1. Induction of platelet-derived growth factor gene expression during megakaryoblastic and monocytic differentiation of human leukemia cell lines
2. Neurotrophins and depression
3. Practice guideline for the treatment of patients with schizophrenia. III. Treatment principles and alternatives
4. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration
5. Inhibition of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor expression reduces dopaminergic sprouting in the injured striatum
6. Megakaryocyte synthesis is the source of epidermal growth factor in human platelets
7. The concept of the neuroleptic threshold: An update
8. Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics
9. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication
10. Brain-derived neurotrophic factor transgenic mice exhibit passive avoidance deficits, increased seizure severity and in vitro hyperexcitability in the hippocampus and entorhinal cortex
11. Inositol phospholipid turnover in platelets of schizophrenic patients
12. Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity
13. Are there differences between the secretion characteristics of NGF and BDNF? Implications for the modulatory role of neurotrophins in activity-dependent neuronal plasticity
14. BDNF controls dopamine D3 receptor expression and triggers behavioral sensitization
15. Decreased synaptophysin in the medial temporal lobe in schizophrenia demonstrated using immunoautoradiography
16. Proteins of the exocytotic core complex mediate platelet alpha-granule secretion. Roles of vesicle-associated membrane protein, SNAP-23, and syntaxin 4
17. A developmental perspective on the pathology and neurochemistry of the temporal lobe in schizophrenia
18. Activity-dependent transfer of brain-derived neurotrophic factor to postsynaptic neurons
19. Reduction of the small synaptic vesicle protein synaptophysin but not the large dense core chromogranins in the left thalamus of subjects with schizophrenia
20. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities
21. Performance of heterozygous brain-derived neurotrophic factor knockout mice on behavioral analogues of anxiety, nociception, and depression
22. The neurodevelopmental hypothesis of schizophrenia: Following a trail of evidence from cradle to grave
23. Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor
24. BDNF protein measured by a novel enzyme immunoassay in normal brain and after seizure: Partial disagreement with mRNA levels
25. Cytokine and growth factor involvement in schizophrenia - Support for the developmental model
26. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation
27. The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients
28. Presence of brain-derived neurotrophic factor in brain and human and rat but not mouse serum detected by a sensitive and specific immunoassay
29. Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity
30. The biology of platelet-derived growth factor
31. Nerve growth factor levels in normal human sera
32. Cellular localization of the Trk neurotrophin receptor family in human non-neuronal tissues
33. Molecular machinery mediating vesicle budding docking and fusion
34. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients
35. Abnormal levels of cAMP-dependent protein kinase regulatory subunits in platelets from schizophrenic patients
36. Clozapine treatment of schizophrenic patients. Plasma concentration and coagulation factors
37. Depresssion - Emerging insights from neurobiology
38. Human platelets contain brain-derived neurotrophic factor
39. Increased turnover of platelet phosphatidylinositol in schizophrenia
40. Decreased serotonergic responsivity in platelets of drug-free patients with schizophrenia
41. Cortical degeneration in the absence of neurotrophin signaling: Dendritic retraction and neuronal loss after removal of the receptor TrkB